The Most Significant Fenbendazole & Ivermectin Cancer Case Reports: A Spotlight Analysis (2026)
|
Quick Answer Of the 760 case reports describing antiparasitic drug protocols (fenbendazole, ivermectin, or mebendazole) in patients with cancer, the most clinically notable outcomes fall into three broad categories: (1) rapid complete or near-complete remissions in patients whose disease had progressed despite conventional therapy, (2) imaging-confirmed tumor regressions ranging from 40% to 99%, and (3) patients receiving hospice care or given a prognosis of only weeks to live who survived substantially longer than expected. Only a small fraction of these 760 cases have been published in peer-reviewed journals; the remainder are self-reported anecdotal accounts. Accordingly, these reports should be regarded as hypothesis-generating observations rather than evidence of clinical efficacy or proof of treatment benefit. |
In This Article
1. How These Cases Were Selected
This spotlight draws from our full case compilation, Fenbendazole, Ivermectin and Mebendazole for Cancer: Case Series of 760 Case Reports. Rather than listing every case, we applied three filters to surface the reports most useful to patients, caregivers, and clinicians trying to gauge signal from noise:
- Magnitude of response — complete remissions, or partial responses large enough to be unambiguous on imaging (generally ≥40% volumetric reduction).
- Clinical desperation at baseline — patients who had exhausted, failed, or declined standard-of-care options before starting the protocol.
- Evidentiary strength — whether the case was independently documented (imaging reports, published in a journal) versus a self-report relayed secondhand.
Every case below should still be read as an anecdotal case report, not a clinical trial result. Case reports are a recognized but low tier of medical evidence — useful for generating hypotheses, not for establishing that a treatment works.
2. Complete & Near-Complete Remission Cases
Stage 4 Cholangiocarcinoma, 53-Year-Old Canadian Woman
The single most cited case in the entire compilation. A 15 cm tumor, progression on both chemotherapy and immunotherapy, and a prognosis discussion with two oncologists preceded the start of a fenbendazole, ivermectin, and melatonin protocol (with CBD/THC added later). She was declared cancer free at roughly 14 months. This case anchors the entire "right to try" narrative around the protocol.
Diffuse Large B-Cell Lymphoma, 60-Year-Old Massachusetts Man
Stage 4 disease with bone metastasis and a 6 cm mass reached complete remission in under two months on ivermectin, fenbendazole, and IP6 — one of the fastest complete responses in the dataset.
Klatskin Tumor (Cholangiocarcinoma), 85-Year-Old Toronto Man
Complete remission in four months using comparatively mild doses of ivermectin, fenbendazole, and CBD — notable because radiation therapy had already failed to halt tumor growth before the protocol began.
Follicular Lymphoma, 83-Year-Old Florida Man
Approximately 99% nodal resolution at six months, achieved entirely without chemotherapy or radiation, starting from a "watch and wait" baseline. The follow-up radiology report reportedly described the change as dramatic. This case is useful because it isolates the protocol's effect without any concurrent conventional treatment.
Pediatric Stage 4 Sarcoma (Radiation-Induced), 12-Year-Old California Boy
Cancer-free at three months despite metastases to the brain, neck, and chest lymph nodes. One of the only pediatric cases in the series and one of the fastest complete responses recorded.
3. Fastest and Most Dramatically Quantified Responses
These cases stand out less for reaching full remission and more because the response was precisely measured — giving readers concrete numbers rather than qualitative impressions.
| Case | Cancer Type | Quantified Result | Timeframe |
| 60yo Oregon woman | Mantle Cell Lymphoma | 87–96% shrinkage across multiple nodes | 3.5 months |
| 44yo Australian man | Hepatocellular Carcinoma | 46% tumor volume reduction; lesion 37mm→30mm; markers -25% | 3 months |
| 56yo Illinois man | Chronic Myeloid Leukemia | Major molecular response (normally an 18-month milestone) | Faster than typical benchmark |
| 49yo Georgia man | Diffuse Large B-Cell Lymphoma, Stage 4 | Near-complete response with zero chemotherapy cycles completed | 3 months |
4. Heavily Pretreated Patients With No Other Options
These are, from an evidentiary standpoint, the most persuasive cases in the series — not necessarily because the tumor response was the largest, but because the patients had genuinely run out of conventional pathways before starting.
The Ridgway Cohort — 16 Patients Given 1–4 Weeks to Live
Reported via journalist Mary Beth Pfeiffer's coverage of physician Mike Ridgway's patients, this is the single strongest cluster for the "exhausted every option" narrative in the entire compilation. Thirteen of sixteen patients given a terminal timeline of one to four weeks survived six to ten months on the protocol; one pancreatic cancer patient survived over a year. The cohort also references Rohini Hughes, an advanced colon cancer patient alive twenty months after being told she had only days left.
Stage 4 Cholangiocarcinoma, 48-Year-Old Texas Woman
Already in hospice care with multi-organ failure at the time she began the protocol. She used it in her final weeks and outlived clinical expectations, though she ultimately passed away. Included here deliberately as a reminder that "heavily pretreated" cases don't always end in remission — sometimes the outcome is modestly extended time, not survival.
73-Year-Old Massachusetts Man, Dual Liver Cancers, Transplant Candidate
Used the protocol while on the liver transplant waiting list. His tumors shrank enough for the transplant to proceed — a case where the protocol arguably bridged him to a curative conventional treatment rather than replacing one.
Diffuse Large B-Cell Lymphoma, 49-Year-Old Georgia Man
Became too sick after his first chemotherapy cycle to continue treatment, leaving no remaining conventional path at the time he started the protocol.
Multiple Myeloma, 67-Year-Old New Jersey Man
Ninety percent of his bone marrow was already infiltrated with malignant cells at diagnosis. Reached remission at six months.
PEComa, 57-Year-Old Slovenian Man
An ultra-rare sarcoma subtype with no established standard-of-care regimen. Initial low-dose treatment failed to stop progression; escalating the dose reversed it. Useful as an example of dose-response reasoning within a single patient.
5. The Peer-Reviewed Cases
Out of 760 cases, only a small number were published in peer-reviewed journals rather than relayed through social media. These carry more evidentiary weight and deserve to be highlighted separately rather than blended in with anecdotal reports.
83-Year-Old Man, Diffuse Large B-Cell Lymphoma (Annals of Hematology & Oncology, 2020)
Declined chemotherapy outright due to its side-effect profile and self-treated with fenbendazole alone. One of the few cases in the series with an independent journal publication behind it.
41-Year-Old Thai Woman, Platinum-Resistant Ovarian Cancer (Case Reports in Oncological Medicine, 2023)
Genuinely pretreated and refractory to platinum chemotherapy, with tumor markers and quality of life improving on the protocol. Included deliberately as a modest, mixed-outcome case: progression-free survival was only two months and overall survival 8.5 months. Not every peer-reviewed case is a dramatic remission story, and presenting this one alongside the more striking anecdotes gives a more honest picture of the range of outcomes.
6. Evidence Quality: What These Cases Can't Tell Us
- Single-narrator concentration. The large majority of the 760 cases are relayed through one physician-aggregator, Dr. William Makis, rather than independently reported by treating physicians.
- No denominator. None of the cases report how many patients on the same protocol did not respond or worsened, which makes it impossible to estimate a true response rate from this dataset.
- Survivorship and selection bias. Case reports are, by nature, more likely to be shared when the outcome is positive.
- Concurrent treatment. Several of the most dramatic responses (the transplant candidate, several lymphoma cases) occurred alongside conventional therapy, low-dose naltrexone, or other supplements, making it difficult to attribute the outcome to any single agent.
None of this means the cases are meaningless — case reports have historically been the first signal behind several now-standard cancer therapies. It means they should be presented to readers as exactly what they are: a starting point for further research, not a substitute for it.
7. Frequently Asked Questions
What is the single most significant case in the series?
The 53-year-old Canadian woman with Stage 4 cholangiocarcinoma who was declared cancer free after roughly 14 months, following failure of chemotherapy and immunotherapy on a 15 cm tumor.
Are these case reports peer-reviewed medical evidence?
Only a small minority are. Most of the 760 cases are self-reports relayed through social media and aggregated by independent physicians. A few, including a diffuse large B-cell lymphoma case and a platinum-resistant ovarian cancer case, were published in peer-reviewed journals.
What does "heavily pretreated with no other options" mean here?
Patients who had already failed, could not tolerate, or were told there was no further standard-of-care treatment available — including patients in hospice, patients who declined further chemotherapy due to side effects, and patients given a survival timeline of weeks.
8. Related Resources
|
Sourcing Ivermectin & Mebendazole Patients researching these protocols often look for verified, pharmaceutical-grade sourcing and physician-backed guidance. The Wellness Company offers consultations and access to ivermectin and related medications with physician oversight. Use referral code ONEDAYMD at checkout. |
Disclaimer: This article summarizes anecdotal and published case reports for informational and research purposes only. It is not medical advice and does not constitute a recommendation for any treatment. Case reports represent a low tier of medical evidence and individual results are not predictive of outcomes for other patients. Consult a qualified oncologist before making any treatment decisions.
.png)
.png)
Comments
Post a Comment